French veterinary pharmaceutical companies Ceva Santé Animale, based in Libourne, and Sogeval (a subsidiary of Sofiprotéol), based in Laval announce the opening of exclusive negotiations to create a future alliance.

The management teams of the two French companies are looking into a strategic alliance that would give them a strong position among the world leaders in animal health.

• Sogeval, 5th French animal health company, specialises in the development, manufacture and marketing of veterinary drugs and speciality products. The firm has been growing steadily and now plays a major role in the prevention and treatment of diseases in both companion animals and livestock. The company operates internationally through 3 subsidiaries (USA, UK and Denmark) and a network of over 60 distributors worldwide.

• Ceva, 9th global veterinary health group, focused on the research, development, productionand marketing of pharmaceutical products and vaccines for companion animals, ruminants,pigs and poultry. Ceva is directly present in 43 countries and has active business in more than 110.

Strong complementarities

• in the Companion Animal sector… Ceva and Sogeval have developed similar expertise in two areas (cardiology and pain management) that will allow them to consolidate their positions. Each has developed specific complementary knowhow for dogs and cats:

" Sogeval - Antibiotic treatment and dermatology.
" Ceva - Anti-parasitics and behaviour.
 
• in Livestock Production sector...

Ceva and Sogeval both have significant expertise in the development and formulation of antibiotics for livestock. Plus a strong portfolio of vaccines and products for the management and control of reproduction.
Beyond these complementarities at a product level, there are also geographical factors that make the two companies a perfect match. The strength of Sogeval in France and that of Ceva internationally will be decisive in strengthening their respective positions in both the domestic and international markets.
Opportunities for specialisation in non-pharmaceutical livestock business The development of biosecurity and nutritionals will continue to be managed by Sofiprotéol, for which this is a strategic priority. The proposed alliance with Ceva will give this activity the benefit of an international partner.

Shared corporate values

Going beyond business expertise, the two companies share very similar values: especially a sense of innovation, entrepreneurial spirit and solidarity between individuals.
For José Daoudal, Sogeval CEO: "We are looking forward to a partnership based on obvious synergies: for Sogeval this alliance would create the opportunity to accelerate our development by rolling out our expertise globally."
For Marc Prikazsky, President & CEO of Ceva: "This decision behind this project was made with both our heart and minds. We share the same business philosophy, one which will allow us to grow faster together, strengthening our position in France and using this base to further develop internationally."

About Ceva :

Ceva Santé Animale is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry. The company had sales o €608M in 2012 and employs 3,000+ people worldwide. Its headquarters are in Libourne, France.
Website: www.ceva.com
 
About Sogeval :

French veterinary pharmaceutical company based in Laval, a Sofiprotéol subsidiary founded in 1978. Sogeval develops, manufactures and markets veterinary drugs and speciality products, under its own brand and for third-party companies.
Located in the heart of Europe’s largest agrifood region, Sogeval has experienced continuous growth and now plays a major role in the prevention and treatment of animal diseases.
Sogeval today employs 291 people including 236 in France. The CEO of Sogeval is José Daoudal.
Website: www.sogeval.fr